Physician profile
Jenchen Yang
NPI 1912084534
$10,036.81
in general payments reported to CMS, 2019-2025
29 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,873 · 2020: $551 · 2021: $855 · 2022: $997 · 2023: $753 · 2024: $3,438 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,579 · Consulting Fee: $2,025 · Travel and Lodging: $147 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,578.51 |
| Consulting Fee | $2,025.00 |
| Travel and Lodging | $147.25 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,924.48 | 2019-2025 | |
| Amgen INC. | $1,140.96 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $1,032.57 | 2019-2024 | |
| United Therapeutics Corporation | $675.07 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Merck Sharp & Dohme LLC | $654.69 | 2019-2025 | Winrevair, Verquvo |
| Esperion Therapeutics, INC. | $383.66 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.09 | 2019-2023 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $271.57 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $199.75 | 2019-2023 | Livalo |
| Philips North America LLC | $186.75 | 2024 | (Bh4) Igt Devices Undivided, (9520) Igt Devices Undivided |
| Amarin Pharma, INC. | $178.90 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $173.62 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $145.82 | 2019-2025 | Amvuttra |
| Novo Nordisk INC | $130.75 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $125.32 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $119.42 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $57.85 | 2022-2024 | Mounjaro |
| Pfizer INC. | $54.88 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.66 | 2022-2025 | |
| Allergan, INC. | $36.49 | 2019 | |
| Edwards Lifesciences Corporation | $33.32 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $33.15 | 2025 | General - Therapies |
| Arbor Pharmaceuticals, INC. | $26.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.19 | 2024 | Camzyos |
| Abbvie INC. | $22.13 | 2023 | Linzess, Viberzi |
| Liquidia Technologies, INC. | $22.08 | 2025 | Yutrepia |
| Glaxosmithkline, LLC. | $19.72 | 2019 | |
| Gilead Sciences, INC. | $17.29 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.26 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenchen Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.